Last updated 3 days ago

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

3000 patients around the world

Available in Argentina, Brazil, Mexico, Puerto Rico, United States

Eli Lilly and Company

47Research sites

3000Patients around the world

This study is for people with

Obesity

Diabetes

Diabetes mellitus type 2

Cardiovascular disease

From 45 Years

All Gender

: Have type 2 diabetes.
Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening.
Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening.
Have an increased risk of cardiovascular events.
Have a BMI ≥ 25.0 kg/m2 at screening.
Have a stable body weight (<5% body weight change) for 90 days prior to screening.
Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.

: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening).
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening).
Have type 1 diabetes.
Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure.
Have had within 60 days prior to screening.
Acute myocardial infarction.
Stroke.
Hospitalization for congestive heart failure, or.
Coronary, peripheral, or carotid artery revascularization procedure.
Have received treatment combining sulfonylurea and insulin within 90 days prior to screening.